Daymark Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Daymark Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$209K	Buy	+904	New	+$223K	﹤0.01%	822

Other funds holding JAZZ

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Daymark Wealth Partners's JAZZ Position: Q3 2026 in Review

Daymark Wealth Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q3 2026: 904 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #822 among its holdings.

333 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

Daymark Wealth Partners held 904 shares of Jazz Pharmaceuticals worth $209K as of Q3 2026.
Jazz Pharmaceuticals was a new Daymark Wealth Partners position in Q3 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Daymark Wealth Partners's portfolio in Q3 2026, its #822 holding.
333 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Daymark Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.